Separating signal from noise: the challenge of identifying useful biomarkers in sepsis

Russell J McCulloh1,2* and John A Spertus2,3

See related review by Zonneveld et al., http://ccforum.com/content/18/1/204

Abstract

Sepsis diagnosis remains based largely on clinical presentation despite significant advances in the understanding of underlying pathophysiology and host-pathogen interactions. The systematic review article by Zonneveld and colleagues in the previous issue of Critical Care describes another potential avenue of study for using biomarkers for sepsis diagnosis and prognostication. Soluble leukocyte adhesion molecules and their associated sheddase enzymes vary in detectable levels and activity in patients in relation to immunologic status, age, and systemic inflammation, including in the setting of sepsis. Unfortunately, studies of these molecules as diagnostic or prognostic aids (or both) in sepsis have thus far been disappointing. Zonneveld and colleagues propose two potential avenues to enhance the performance characteristics of soluble adhesion molecules and their sheddases in sepsis diagnosis and prognosis: (a) identifying age-adjusted normal values for soluble leukocyte adhesion molecules and their sheddases and (b) investigating simultaneous measurement of both soluble adhesion molecules and sheddases in integrated sepsis evaluation schema. This commentary discusses the proposed solutions of Zonneveld and colleagues in more detail and outlines additional considerations that should be addressed in order to develop robust and valid diagnostic and prognostic tools for clinicians managing patients with sepsis.

Introduction

The article by Zonneveld and colleagues [1] in the previous issue of Critical Care highlights the ongoing challenge in identifying and treating septic patients. Few human maladies prove more resistant to modern diagnostic and theragnostic techniques than sepsis. Despite research describing much of the underlying pathophysiology, sepsis remains a diagnosis based primarily on clinical presentation [2]. Many attempts at identifying biomarkers that aid in diagnosis or mortality risk estimation have met with limited success [3]. The elusiveness of reliable biomarkers in sepsis stems partly from the byzantine, interdependent immune processes contributing to the sepsis syndrome. Zonneveld and colleagues review the complex interplay of one set of processes. Leukocyte adhesion molecules, and the sheddase enzymes catalyzing the release of their soluble fragments into the bloodstream, participate in the homeostasis of immune responses that direct leukocytes to sites of injury, infection, and/or inflammation. The authors review previous failed attempts to use soluble adhesion molecules and sheddases as diagnostic biomarkers. Undaunted by the litany of failures identified in their review, Zonneveld and colleagues describe two key avenues of inquiry that may reveal the usefulness of soluble leukocyte adhesion molecules and their sheddases in sepsis diagnosis and prognosis.

Proposed avenues of inquiry

First, the authors posit that understanding the variation in circulating levels of soluble adhesion molecules and sheddases by patient age will help better define normal values in neonatal, pediatric, and adult sepsis. More accurately defining these normal ranges could improve the diagnostic and prognostic accuracy of these molecules in sepsis. To support this assertion, the authors review several studies describing developmental differences in circulating levels of soluble adhesion molecules and sheddase activity between neonates, children, and adults.

* Correspondence: rmcculloh@cmh.edu
1Division of Pediatric Infectious Diseases, Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
2University of Missouri-Kansas City School of Medicine, 2411 Holmes Road, Kansas City, MO 64198, USA

Full list of author information is available at the end of the article

© 2014 McCulloh and Spertus; licensee BioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors’ findings are similar to published studies of other age-related differences in aspects of the immune system. For example, CD4+ T-cell counts based on patient age (for example, a Z-score) better predict opportunistic infection risk in HIV-positive children than absolute CD4 counts [4,5]. Age-stratified values have also been suggested for evaluating the use of sepsis biomarkers in older patients [6].

Second, Zonneveld and colleagues propose that measuring soluble adhesion markers and their sheddases simultaneously may provide greater diagnostic and prognostic capabilities than measuring either category separately. Their assertion is important because the complex, interrelated nature of the immunologic response to sepsis most likely cannot be distilled to a single component. Prognosis is undoubtedly related to numerous factors, including biomarker-associated measures of sepsis severity, age, comorbidities, disease severity (for example, oxygenation, organism, or etiology of the septic episode), and other factors contributing to mortality. Evaluation strategies thus should seek to integrate the contributions of multiple potentially prognostic elements.

The challenge, therefore, is to develop a research strategy that provides the infrastructure capable of modeling the heterogeneity of patient outcomes. The literature reviewed by Zonneveld and colleagues is woefully inadequate to do this. Few of the studies report the association of biomarker changes to outcome, and all are limited by very small sample sizes. Ideally, researchers need to assemble a large, multi-center cohort that exquisitely characterizes septic patient demographics, medical comorbidities, disease severity, and sepsis-associated biomarkers. The PROGRESS (Promoting Global Research Excellence in Severe Sepsis) registry represents an attempt to create such a cohort but was limited by variation in reporting rates and lack of data integrity assurance measures [7]. Most importantly, the ideal registry needs to accurately document patient outcomes. From such an observational registry, researchers could build multi-variable models of mortality, in which the independent prognostic importance of each variable could be determined, along with any possible interactions. In other disciplines, such as cardiology or clinical trials, such multi-variable models have been invaluable in modeling the heterogeneity of risk and treatment benefits and can be used to guide therapy and improve outcomes [8-12].

Accomplishing this goal will require substantial commitment and collaboration among those interested in building better sepsis prognostic strategies. If, as a simple rule of thumb, 10 mortality events are required for each potential predictor variable and 20% of patients with sepsis die, then for 10 potential predictors (not including interactions) to be identified, a minimum of 500 patients with severe sepsis would need to be enrolled to perform such an analysis, which represents a major effort. This commitment is critical, however, to developing tools and strategies to improve prognostication, incorporate evolving insights into sepsis pathophysiology, and use this information to better tailor therapy and improve outcomes.

Conclusions

We commend Zonneveld and colleagues for their systematic review of the leukocyte adhesion molecule-sheddase system in sepsis. Their work highlights the needs for more sophisticated methods to define prognosis and for challenging the research community to be sensitive to potential age-based interactions. The job for researchers and policymakers now is to invest in collecting the data from large, multi-site cohorts and to rigorously analyze the information so that better tools for prognostication can be developed. Once available, these tools can become foundational for better informing patients and families about prognosis, improving diagnostic testing, and directing treatments to those who most benefit.

Competing interests

The authors declare that they have no competing interests.

Author details

1Division of Pediatric Infectious Diseases, Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA. 2University of Missouri-Kansas City School of Medicine, 2411 Holmes Road, Kansas City, MO 64198, USA. 3Saint Luke’s Mid America Heart Institute, 4401 Wornall Road, Kansas City, MO 64111, USA.

Published: 17 Mar 2014

References

1. Zonneveld R, Martinelli R, Shapiro NI, Kuipers TW, Plotz FB, Carman CV: Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care 2014, 18:204.
2. Dellinger RP, Levy MM, Rhodes A, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Antonson DJ, Taichman DB, Caplan RA, Perel M, Carcillo J, Wiedower C, Trzeciak S, Slate J, Parrilli M, Sibbald W, Dellinger EP, Levy SM: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. 2012. Crit Care Med 2013, 39:165–228.
3. Ventetuolo CE, Levy MM: Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008, 29:591–603. vii.
4. HIV Paediatric Prognostic Markers Collaborative Study: Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006, 20:1289–1294.
5. HIV Paediatric Prognostic Markers Collaborative Study, Boyd K, Dunn DT, Castro H, Gibbs DM, Duong T, Aloukier JP, Bulterys M, Cobas-Borja M, Gabiano C, Galli L, Giagunto C, Harris DR, Hughes M, McKinney R, Mofenson LM, Moye J, Newell ML, Pahwa S, Palombo P, Rudin C, Shafland M, Shearer W, Thompson B, Tookey P: Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 2010, 24:1213–1217.
6. Wang JC, Aasen AO: Is inter-alpha inhibitor important in sepsis? Crit Care Med 2007, 35:634–635.
7. Beale R, Reinhart K, Brunnhorst FM, Dobbs G, Levy M, Martin G, Martin C, Ramsey G, Silva E, Valtat B, Vincent JL, Janes JM, Sarwat S, Williams MD; PROGRESS Advisory Board: Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009, 37:222–232.
8. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, Ou FS, Roe MT, Peterson ED, Marso SP; National Cardiovascular Data Registry: Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv 2009, 2:222–229.

9. Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, Cohen DJ, Messenger JC, Rumsfeld JS; National Cardiovascular Data Registry: Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 2010, 303:2156–2164.

10. Hayward RA, Kent DM, Vijan S, Hofer TP: Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 2006, 6:18.

11. Rao SC, Chhatriwalla AK, Kennedy KF, Decker CJ, Gialde E, Spertus JA, Marso SP: Pre-procedural estimate of individualized bleeding risk impacts physicians’ utilization of bivalirudin during percutaneous coronary intervention. J Am Coll Cardiol 1847–1852, 2013;61.

12. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA: Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010, 11:85.